The Latest Cardiac and Vascular News
DUBLIN – April 17, 2018 – Medtronic plc (NYSE: MDT) today announced its U.S. launch of OptiSphere(TM) embolization spheres, a resorbable embolic platform designed for embolization of hypervascular tumors. OptiSphere offers patients an alternative treatment option, a resorbable embolic, with comparable results to a permanent embolic.1 Hypervascular tumors can present as […]
DUBLIN – April 5, 2018 – Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced Laura Mauri, M.D., M.Sc., interventional cardiologist and clinical researcher at the Brigham and Women’s Hospital, and professor of medicine at Harvard Medical School, will join Medtronic as Vice President, Global Clinical Research & […]
DUBLIN – April 9, 2018 – Medtronic plc (NYSE:MDT) today announced U.S. Food and Drug Administration (FDA) approval to begin an investigational device exemption (IDE) pivotal trial to evaluate the Symplicity Spyral(TM) renal denervation system in patients with high blood pressure (hypertension). Renal denervation is a minimally invasive procedure intended […]
Presented at ACC.18, Five-Year Follow-up from the CoreValve Extreme Risk and NOTION Studies Show Sustained Valve Function and Durability Over Time DUBLIN and ORLANDO – March 10, 2018 – Medtronic plc (NYSE: MDT) today unveiled outcomes from the CoreValve U.S. Pivotal Extreme Risk Study and the real-world NOTION trial (Nordic Aortic […]
FDA Approved, Resolute Onyx 2.0 mm DES Technology Tackles Clinical Challenge of Treating Coronary Artery Disease in Previously Untreatable Patients DUBLIN – February 26, 2018 – Designed specifically for small vessels, Medtronic plc (NYSE: MDT) today announced the U.S. Food and Drug Administration (FDA) approval and U.S. launch of the Resolute […]
This first of it’s kind trial compares two leading DCB technologies. Boston Scientific’s drug-coated balloon goes up against Medtronic’s DCB in first-of-its-kind trial JANUARY 31, 2018 BY SARAH FAULKNER, Drug Delivery Business NEws Top-line results from a head-to-head trial comparing Boston Scientific‘s (NYSE:BSX) Ranger drug-coated balloon and Medtronic‘s (NYSE:MDT) In.Pact Admiral DCB found no […]
Medtronic Completes the Purchase of QT Vascular’s Chocolate PTA Balloon Catheter Highlights: – Medtronic completes the purchase of the Company’s non-drug coated Chocolate® PTA balloon catheter – The completion of this purchase validates the value of this internally developed specialty PTA to improve outcomes in patients with peripheral artery disease PLEASANTON, Calif., […]
IN.PACT Admiral Demonstrates Consistent and Durable Outcomes in New Two-Year Japan Data and IN.PACT Global Critical Limb Ischemia Cohort Analysis Data Presented at LINC 2018 Highlight IN.PACT Admiral as Safe and Effective Treatment Option in PAD DUBLIN and LEIPZIG – January 30, 2018 – Medtronic (NYSE: MDT) today added to its robust […]
Study to Enroll Subjects at up to 35 Sites Across the U.S. and Europe DUBLIN – January 26, 2018 – Medtronic plc (NYSE: MDT) today announced the initiation of its investigational device exemption (IDE) study for the Abre(TM) venous self-expanding stent system. The ABRE IDE Study will evaluate the safety and […]
DUBLIN – January 16, 2018 – Medtronic plc (NYSE:MDT) today announced that the company’s Neurovascular business unit received U.S. Food and Drug Administration (FDA) clearance of the Riptide(TM) Aspiration System, adding a valuable tool to the Acute Ischemic Stroke (AIS) product portfolio. The Riptide Aspiration System is designed to retrieve thrombus […]
